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Resistance to apoptosis is well documented as one of the 
hallmarks of cancer,
1
 and the Bcl-2 family of proteins play a 
critical role in regulating the intrinsic apoptosis process in 
response to apoptotic stimuli. The structurally related Bcl-2 
protein family is structurally and functionally classified as either 
anti-apoptotic (e.g. Bcl-2, Bcl-xL, Bcl-w, Mcl-1); pro-apoptotic 
(e.g. Bak, Bax, Bcl-rambo); or as pro-apoptotic BH3 domain 
only proteins (e.g. Bad, BID, Bim, Noxa) that bind and regulate 
anti-apoptotic Bcl-2 proteins. The carefully regulated balance 
between pro- and anti-apoptotic protein family members is 
crucial in dictating cellular survival or commitment to apoptosis.
2
  
In terms of development of new cancer therapeutics, small 
molecule anti-apoptotic Bcl-2 inhibitors offer exciting prospects.
3
 
Following Bcl-2 inhibition, the resulting cellular mitochondrial 
membrane permeabilisation and release of pro-apoptotic factors 
commits the cell to apoptosis and subsequent removal. 
Resistance to apoptotic stimuli is commonly induced by over-
expression of anti-apoptotic Bcl-2 proteins that are also known to 
contribute to therapy failure and subsequent generation of a more 
resistant cancer phenotype.
2
  
The exciting potential of small molecule anti-apoptotic Bcl-2 
inhibitors in cancer therapy has led to a number of advances in 
this area,
3,4
 focusing on the design of new cell permeable small 
molecule inhibitors that block sites of protein-protein interaction
5
 
between anti-apoptotic Bcl-2 family proteins and pro-apoptotic 
partners. Amongst the most advanced and well-documented 
examples of Bcl-2 inhibitors that have progressed to clinical 
evaluation are the orally bioavailable navitoclax (ABT-263, 1), 
obatoclax (2) and the polyphenolic natural product-based 
experimental drug gossypol (3), shown in Figure 1. Perhaps most 
significantly, the Bcl-2 inhibitor venetoclax (ABT-199, 4) has 
been granted breakthrough designation by the FDA for treatment 
of patients with relapsed or refractory chronic lymphocytic 
leukaemia (CLL) who have the 17p chromosomal deletion.
6
  
One notable feature of the first generation of anti-apoptotic 
Bcl-2 family inhibitors is their large size (Mr = 975 in the case of 
navitoclax) and chemical complexity, in part arising from the 
perceived requirement to make multiple drug binding interactions 
across a substantial protein-protein interaction interface. The 
development of smaller, less complex molecules that retain 
selective Bcl-2/Bcl-XL inhibition and antitumour activity is an 
ongoing challenge. The pro-apoptotic Bcl-2 inhibitory compound 
obatoclax mesylate
7
 suggests that structurally simple heterocylic 
compounds may possess the necessary characteristics for 
selective Bcl-2 inhibitory antitumour properties. Previous work 
within our group has identified pro-apoptotic Bcl-2 inhibitory 
compounds of the indolyl-oxadiazole,
8
 isoxazole
9
 and indolyl-
triazole
10
 classes; in this paper we report the discovery and early 
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evaluation of a new series of Bcl-2 inhibitory 5-(1H-indol-3-yl)-
N-aryl-1,3,4-oxadiazol-2-amines. 
Figure 1. Examples of small molecule Bcl-2 inhibitors.  
The lead compound for this study (8a) was obtained as a 
virtual screening hit of the ZINC database against a Bcl-2 
pharmacophore model, using methodology previously 
described.
11
 Structure activity relationships were studied by 
variation of the phenyl/benzyl group substituents that bind within 
a hydrophobic groove of our model, as shown in Scheme 1.  
Scheme 1: Synthesis of indolyl-N-aryl-oxadiazolamines. 
Synthesis of the target compounds was readily achieved in 
two synthetic steps, through adaptation of a literature route.
12,13
 
The first step involved heating indole-3-carbonylhydrazide (5) 
with substituted phenyl/benzyl isothiocyanates (6a-j) in refluxing 
ethanol to produce the intermediate thiosemicarbazide (7a-j) that 
was used in the next step without further purification.
14
 
Treatment of the indolyl-3-carbonyl-N-phenyl/benzyl 
thiosemicarbazide (7a-j) with KI and 1,3-dibromo-5,5-
dimethylhydantoin in basic solution afforded the product 5-(1H-
indol-3-yl)-N-aryl-1,3,4-oxadiazol-2-amines (8a-j) in high yield 
(58-86%) following recrystallisation from ethanol.
15,16
 
Evaluation of the newly synthesized indolyl-oxadiazolamines 
was carried out across four human cancer cell lines. Viability in 
the established triple-negative breast cancer cell line MDA-MB-
231 and cervical cancer (HeLa) cells (both Bcl-2 expressing) was 
assessed using the MTT endpoint assay. To test the effect of 
differing Bcl-2 status, further evaluation of new compounds was 
carried out in the human cancer cell lines KG1a (acute 
myelogenous leukaemia) and Jurkat (T cell leukaemia). The 
Jurkat cell line has previously been characterized as Bcl-2 
negative by our group
17
 and others,
18
 unlike the Bcl-2 expressing 
KG1a cell line.
19
 For studies on the leukaemic cells we used the 
CellTiter-Blue® viability assay, appropriate for endpoint 
determinations in these non-adherent cells. The results, expressed 
as mean values following testing on at least three separate 
occasions, are presented in Table 1. 
The results shown in Table 1 indicated that in general the 
HeLa cell line was the most sensitive to the effects of test 
compounds with IC50 values in the sub- to low-micromolar range 
of 0.3 – 19 µM (with the exception of inactive compound 8g). 
The MDA-MB-231 breast cancer cell line also gave sub- to low-
micromolar IC50 values for the majority of new compounds. The 
observation of sub- to low-micromolar inhibitory activity for the 
majority of compounds in the Bcl-2 expressing KG1a leukaemic 
cell line, but not in the Bcl-2 negative T-cell leukaemia Jurkat 
cells, suggests that Bcl-2 may play a role in mediating the 
observed anticancer activity. 
The most active compound overall was the 2-nitrophenyl 
derivative 8a that shows potent (sub-micromolar) IC50 values 
across the three Bcl2-expressing human cancer cell lines (MDA-
MB-231, HeLa and KG1a) with less potent inhibitory activity in 
the Bcl-2 negative Jurkat cells. The most active and selective 
compounds from the cell line assay (8a, 8c and 8e), along with 
moderately active compounds 8h and 8i were chosen for more 
detailed mechanistic study using the enzyme-linked 
immunosorbent (ELISA) sandwich binding assay along with 
gossypol as positive control.  
The ELISA assay was used to determine the ability of the test 
compounds to compete with immobilized Bim peptide for 
binding to His-tagged Bcl-2 protein, according to our previously 
described protocol
10,19
 (see Supplementary Information). The 
ELISA binding results (Table 2) displayed some consistency with 
the predicted activity of the killing pattern, in that the potently 
active compound 8e showed similar binding affinity to Bcl-2 
compared with reference standard gossypol. Compound 8e was 
found to be two-fold more active than our initial lead compound 
8a. 
Compound number ELISA IC50, µM 
8a 1.24 ± 0.18 
8c 3.83 ± 0.05 
8e 0.66 ± 0.06 
8h 21.12 ± 0.18 
8i 29.05 ± 0.17 
Gossypol (3) 0.60 ± 0.09 
Table 2. ELISA binding activity values (IC50) for selected compounds. 
Results are expressed as triplicate testing mean values. 
 
Further evidence that Bcl-2 might be responsible for the 
observed anticancer activity of the new indolyl-N-aryl-
oxadiazolamines was obtained through molecular modeling 
studies. Interactions between the most active compounds 8a and 
8e, and a published Bcl-2 crystal structure (PDB code 4AQ3
20
), 
were studied within MOE
21
 making use of the LeadIt software
22
 
for analyzing molecular interactions. Docking of compound 8a at 
the Bim peptide-binding site revealed that 8a mimics residues 
Leu95 and Ile97 of Bim, making important interactions between 
Leu96 and the extracellular NH group, and between Arg105 and 
the oxadiazole ring nitrogen (3-position), within the Bcl-2 
hydrophobic groove. Compound 8e occupies a similar Bcl-2 
binding site mimicking the Phe101, Leu95, and Ile97 residues of 
Bim peptide, similarly making interactions between Leu96 and 
the extracellular NH group, and between Arg105 and the 
oxadiazole ring nitrogen (3-position). For compound 8e, an 
additional interaction between key Bcl-2 hydrophobic groove 
residue Tyr67 and the indole ring of 8a is apparent. 
Representations of the binding models of 8a (A) and 8e (B) 
within the Bcl-2 hydrophobic pocket are shown in Figure 2. 
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Table 1. Growth inhibitory activity (IC50, µM) values for 5-(1H-indol-3-yl)-N-aryl-1,3,4-oxadiazol-2-amines 8a-j in human cancer cell lines MDA-MB-231 
(breast), HeLa (cervical), KG1a (acute myelogenous leukaemia) and Jurkat (T cell leukaemia). Results are expressed as triplicate testing mean values. 
Compound MDA-MB-231 HeLa KG1a Jurkat 
8a 0.90 ± 0.02 0.30 ± 0.04 0.85 ± 0.08 30.2 ± 1.5 
8b 34.6 ± 0.64 15.12 ± 0.32 25.5 ± 0.65 >100 
8c 3.54 ± 0.03 1.76 ± 0.02 0.89 ± 0.04 45.0 ± 1.3 
8d 9.77 ± 0.82 3.80 ± 0.20 3.16 ± 0.19 30.2 ± 1.5 
8e 8.89 ± 0.05 5.60 ± 0.09 32.7 ± 0.68 >100 
8f 31.08 ± 0.6 19.29 ± 1.09 45.3 ± 0.34 >100 
8g >100 >100 21.1 ± 1.6 >100 
8h 27.25 ± 0.98 15.79 ± 0.96 4.00 ± 0.13 >100 
8i 10.08 ± 0.83 5.82 ± 0.07 0.82 ± 0.05 >100 
8j 6.47 ± 0.52 7.81 ± 0.87 >100 ± 0.03 >100 
 
Figure 2. Binding of indolyl-N-aryl-oxadiazolamine hit compounds 8a (A) 
and 8e (B) within the Bcl-2 hydrophobic binding pocket. Only the Bcl-2 
residues involved in hydrogen bonding (Leu-96, Arg-105) or in π-H 
interaction (Tyr-67) with compounds 8a and 8e are represented. 
In conclusion, we have identified the 5-(1H-indol-3-yl)-N-aryl-
1,3,4-oxadiazol-2-amines 8e and 8a as new Bcl-2 inhibitory 
small molecules with moderately potent anti-proliferative activity 
against Bcl-2 expressing human cancer cell lines and Bcl-2 
protein. These new compounds are useful lead compounds for 
further development against this well-established anti-apoptotic 
target. 
Acknowledgments 
We thank the Egyptian Government for the award of a PhD 
studentship (to NIZ) and the award of a Channel Scholarship (to 
RH and SA). We acknowledge the support of Cancer Research 
Wales for a PhD studentship (to CB). We are also grateful to the 
EPSRC UK National Mass Spectrometry Facility at Swansea 
University (U.K.) for provision of compound accurate mass 
determinations. 
References and notes 
1. Hanahan, D.; Weinberg, R. A. Cell 2011, 144, 646. 
2. Chipuk, J. E.; Moldoveanu, T.; Llambi, F.; Parsons, M. J.; Green, 
D. R. Mol. Cell 2010, 37, 299.  
3. Vogler, M.; Dinsdale, D.; Dyer, M. J.; Cohen, G. M. Cell Death 
Differ. 2009, 16, 360. 
4. Ziedan, N. I.; Kadri, H.; Westwell, A. D. Mini Rev. Med. Chem. 
2008, 8, 711. 
5. White, A. W.; Westwell, A. D.; Brahemi, G. Expert Rev. Mol. 
Med. 2008, 10, 1. 
6. Cang, S.; Iragavarapu, C.; Savooji, J.; Song, Y.; Liu, D. J. 
Hematol. Oncol. 2015, 8, 129. 
7. Nguyen, M.; Marcellus, R. C.; Roulston, A.; Watson, M.; Serfass, 
L.; Madiraju, S. R. M.; Goulet, D.; Viallet, J.; Bélec, L.; Billot, X.; 
Acoca, S.; Purisima, E.; Wiegmans, A.; Cluse, L.; Johnstone, R. 
W.; Beauparlant, P.; Shore, G. C. Proc. Natl. Acad. Sci. USA 
2007, 104, 19512. 
8. Ziedan N. I.; Stefanelli, F.; Fogli, S.; Westwell, A. D. Eur. J. Med. 
Chem. 2010, 45, 4523. 
9. Tohid, S. F. M.; Ziedan, N. I.; Stefanelli, F.; Fogli, S.; Westwell, 
A. D. Eur. J. Med. Chem. 2012, 56, 263. 
10. Hamdy, R.; Ziedan, N. I.; Ali, S.; El-Sadek, M.; Lashin, E.; 
Brancale, A.; Jones, A. T.; Westwell, A. D. Bioorg. Med. Chem. 
Lett. 2013, 23, 2391. 
11. Ziedan, N. I. Ph.D. Thesis, Cardiff University, 2010. 
12. Begum, A.; Aparna, A. V.; Sireesha, B.; Devi, C. S.; Raghavaiah, 
P. Ind. J. Chem. B 2009, 48, 1565. 
13. Rivera, N. R.; Balshells, J.; Hansen, K. B. Tetrahedron Lett. 2006, 
47, 4889. 
14. General method for synthesis of indolyl-3-carbonyl-N-
phenyl/benzyl thiosemicarbazide (7a-j). To a solution of indole-3-
carbonylhydrazide (5, 1.0 mmol) in absolute ethanol (100 mL) 
was added a solution of substituted phenyl/benzyl isothiocyanate 
(6a-j) in ethanol (50 mL) with continuous stirring. The reaction 
mixture was heated under reflux for 1h. After cooling to room 
temperature, the precipitate formed was collected by filtration, and 
washed with ice-cold ethanol (30 mL) to give the corresponding 
A 
B 
thiosemicarbazide (7a-j), which was used in the next step without 
further purification.  
15. General method for synthesis of 5-(1H-indol-3-yl)-N-aryl-1,3,4-
oxadiazol-2-amines (8a-j). To a suspension of the indolyl-3-
carbonyl-N-phenyl/benzyl thiosemicarbazide (7a-j, 1.5 mmol) in 
isopropanol (10 mL) was added a solution of potassium iodide 
(1.5 mmol) in water (2 mL) and 5N NaOH (1.5 mmol) at 5 °C, 
and the mixture was stirred until a clear solution was formed. A 
solution of 1,3-dibromo-5,5-dimethyl hydantoin (3.8 mmol) in 
acetonitrile (10 mL) was the added over 1h whilst maintaining the 
temperature below 10 °C. The mixture was stirred for a further 1h 
at 10 °C and then the reaction mixture was quenched with aqueous 
NaHSO3 and the crude product collected by filtration. 
Recrystallisation from ethanol gave the corresponding pure 5-(1H-
indol-3-yl)-N-aryl-1,3,4-oxadiazol-2-amines (8a-j). 
16. Representative characterization data: 5-(1H-Indol-3-yl)-N-(4-
nitrophenyl)-1,3,4-oxadiazol-2-amine (8c): (85% yield). 
1
H NMR 
(DMSO-d6) δ 7.26 (2H, m, ArH), 7.55 (1H, d, J 7.4 Hz, ArH), 
7.84 (2H, d, J 9.1 Hz, H-3’, H-5’), 8.03 (1H, d, J 2.7 Hz, H-2), 
8.11 (1H, d, J 7.0 Hz, ArH), 8.30 (2H, d, J 9.1 Hz, H-2’, H-6’), 
11.40 (1H, bs, NH), 11.91 (1H, bs, NH). 
13
C NMR (DMSO-d6) δ 
99.48 (C-3), 112.38 (ArCH), 116.65 (ArCH), 120.18 (ArCH), 
120.96 (ArCH), 122.78 (ArCH), 123.99 (ArC), 125.48 (ArCH), 
126.93 (ArCH), 136.38 (ArC), 140.80 (ArC), 145.31 (ArC), 
156.54 (ArC), 157.49 (ArC). MS (ESI
+
) 322.1 (M
+
+1). Analysis 
calcd. for C16H11N5O3: C, 59.81; H, 3.45; N, 21.80. Found: C, 
59.46; H, 3.35; N, 21.47. 
17. Watkins, C. L.; Sayers, E. J.; Allender, C. J.; Barrow, D.; Fegan, 
C.; Brennan, P.; Jones, A. T. Mol. Therap. 2011, 19, 2124. 
18. Kolluri, S. K.; Zhu, X. W.; Zhou, X.; Lin, B. Z.; Chen, Y.; Sun, 
K.; Tian, X. F.; Town, J.; Cao, X. H.; Lin, F.; Zhai, D. Y.; Kitada, 
S.; Luciano, F.; O’Donnell, E.; Cao, Y.; He, F.; Lin, J. L.; Reed, J. 
C.; Satterthwait, A. C.; Zhang, X. K. Cancer Cell 2008, 14, 285. 
19. Rao, J.; Xu, D.-R.; Zheng, F.-M.; Long, Z.-J.; Huang, S.-S.; Wu, 
X.; Zhou, W.-H.; Huang, R.-W.; Liu, Q. J. Trans. Med. 2011, 9, 
71. 
20. Research Collaboration for Structural Bioinformatics (RCSB) 
Protein Data Bank (PDB); www.rcsb.org/pdb  
21. Molecular Operating Environment (MOE), Chemical Computing 
Group Inc., Montreal, Canada; www.chemcomp.com  
22. BioSolveIT GmbH; www.biosolveit.de/LeadIT  
Supplementary Material 
Chemical analytical and spectroscopic data (NMR, mass 
spectrometry and % C,H,N elemental analysis) are detailed in 
Supplementary Material, along with detailed protocols for cell 
culture and endpoint assays, plus the Bcl-2 ELISA assay and 
molecular modelling studies. 
 
